Cathepsin D (CD, EC 3.4.23.5) is a lysosomal protease induced by estrogen in certain estrogen receptor (ER)-positive breast cancer cell lines but produced constitutively by ER-negative cell lines. Our aims in this investigation were to study the distribution of CD in human breast cancers and to relate its concentrations to various biochemical, histological, and clinical characteristics. 
Cathepsin D (CD, EC 3.4.23.5) is a lysosomal protease induced by estrogen in certain estrogen receptor (ER)-positive breast cancer cell lines but produced constitutively by ER-negative cell lines. Our aims in this investigation were to study the distribution of CD in human breast cancers and to relate its concentrations to various biochemical, histological, and clinical characteristics. The concentrations of CD were significantly higher in breast carcinomas than in either normal breast tissues or benign breast tumors. In primary carcinomas, CD concentrations did not correlate with the concentrations of ER or with the estrogen-inducible protease t-PA. However, CD concentrations did correlate weakly but significantly with both UK-PA antigen and UK-PA activity. Also, CD concentrations did not correlate with either tumor stage or axillary node status but did correlate significantly with tumor grade. Patients with cancers containing high concentrations of CD had a significantlyshorter overall survivalthan did patients with low concentrations of the enzyme. 
Materials and Methods Handlingof BreastTumors
All breast tissues were examined histologically.
Tumor grade and stage were assessed as previously described by us (4). For the biochemical assays, breast tissues were snap-frozen in liquid nitrogen and then transferred to a -70 #{176}C freezer for no more than two weeks. The tumors were homogenized in 50 nunolIL Tris -HC1 buffer (pH 7.4) as previously described (5) . The homogenates were centrifuged at 2000 x g for 10 mm and the supernates were used for the various biochemical assays described below.
Assay of Total Cathepsin D
We used a one-step double-determinant solid-phase immunometric assay (ELSA-cath-D kit; CIS Bio-industries, Gif-sur-Yvette, France) previously described (6, 7) . The assay involves two monoclonal antibodies, one (D7E3) coated on the ELSA solid phase and the other (M1G8) radiolabeled with 'I. The assay was performed on diluted cytosols from breast tissue ( CathepsinD values >50 nmolIg protein were found more frequently in grade 3 tumors than in either grade 1 or 2 samples (P <0.05, .k test, Table 2 ).
Correlation between cathepsin D and patient prognosis. The relationship between cathepsin D concentrations in primary cancers and both disease-free interval and overall survival is shown in Figure 2 . Patients with concentrations of cathepsin D >40 nmol/g protein have a significantly shorter overall survival than do patients with lower concentrations of the protease (P = 0.0309). 6 The relationship between cathepsin D and disease-free interval is not quite significant (P = 0.062). (8) .
Discussion
Whether UK-PA isestrogen-inducible inbreast cancer is at present unclear. In one study with MCF-7 cells, t-PA 6All of the early work was done with 50 nmol/g as the cutoff value; however, examining various cutoff values for clinical significance showed that 40 nmol/g gave the best differentiation. (20) found that cathepsin D was a significant prognostic marker for disease-free survival in axillary node-negative breast-cancer patients. In our study, too few recurrences or deathshave occurred at this stage of follow-up for us to assess the role of cathepsin D in axillary node-negative breast-cancer patients. This work was supported in part by both The Irish Cancer Society and The Health Research Board of Ireland. We thank International CIS for providing the cathepsin D kits free of charge and A. Defrenne for excellent technical assistance.
